- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00213005
Safety and Acceptability of Carraguard® in HIV Positive Women and Men
A Phase 1 Safety and Acceptability Study of Carraguard® Among HIV Positive Women and Men in Durban, South Africa
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
We proposed a safety study of the Council's lead candidate microbicide, Carraguard® in three cohorts in Durban, South Africa: sexually abstinent HIV-positive women, sexually abstinent HIV-positive men, and sexually active HIV-positive women. Sexually active women must be in an HIV-positive seroconcordant relationship (confirmed by HIV testing of the woman and her male partner) and written informed consent was obtained from the male partners. Women and men in each cohort were randomized to one of three study groups: Carraguard® gel, its matching placebo methyl-cellulose gel, or no product.
The main objectives of this study were to investigate changes in the vulvar, vaginal, and cervical epithelia, the vaginal flora, and HIV-1 shedding in the genital tract of female participants, and changes of the penile skin and epithelia of male participants. We also evaluated symptoms reported by participants, and several dimensions of the acceptability of and compliance with the study or placebo gel. Reactions to a non-contraceptive microbicide were assessed, as well as reasons for voluntary discontinuation and non-use of Carraguard® or the placebo (determined by review of daily diary) was recorded. Exit focus group discussions were held with male and female participants to discuss aspects of acceptability and compliance. Self-reported symptoms were also investigated by clinical examination as needed and study endpoints included genital itching or burning, frequent urination, burning while urinating, genital pain, pain during sex, and abnormal vaginal or penile discharge.
Studientyp
Einschreibung
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Durban, Südafrika
- Medical Research Council
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Positive for HIV-1 by licensed HIV test (with confirmation) and agree to be informed of the test result
- Age 18 to 45 years old, for women (no maximum age for men)
- In good health, defined as CD4+ cell count >200 x 106/L and current absence of opportunistic infections that may interfere with protocol adherence
- If on treatment for HIV infection (including immune-boosters such as Moducare and vitamins): treatment should stay constant for the duration of the study
- For sexually abstinent cohort: Willing to abstain from sexual intercourse and masturbation for the duration of the study (3 weeks) and for the 48 hours before joining the study
- For sexually active cohort: Willing to have sex with only one male partner, and male partner is willing to have sex with only the participant, for the duration of the study
- Regular menstrual cycle (3-5 weeks between periods) or amenorrheic due to long-term (three months or more) DMPA use (and have had no DMPA-related side effects that could interfere with study participation in the last 6 months)
- Planning on living in Durban for the next 6 months
- Willing to refrain from using any other vaginal products for the duration of the study (3 weeks), including other spermicides, diaphragm/cervical cap, traditional drying and tightening agents, douches, tampons, and medicinal products
- Willing and able to comply with all other aspects of the study protocol, including clinical evaluations and study gel administration (if applicable)
- Willing and able to give informed consent.
Exclusion Criteria:
- Currently pregnant, menopausal or lactating, or desire to become pregnant at the time of study participation
- Current or recent participation (within past 30 days) in any other clinical trial, including trials of HIV therapeutics and trials of vaginal products (this does not include the ongoing study in the Department of Paediatrics of King Edward VIII Hospital)
- Delivery, miscarriage or abortion within the last six weeks
- Gynecological surgery or instrumentation in the last three months
- History of non-menstrual vaginal bleeding with intercourse in the last month
- Presence of a clinically detectable genital abnormality (i.e. vulvar, vaginal, cervical and/or perianal ulcer and/or lesion) on which the epithelium is currently disrupted or is likely to disrupt (e.g. herpes blister). Women with healed/dried-up lesions from a past infection, or with a lesion on which the epithelium is currently intact or unlikely to disrupt, will be eligible for enrollment.
- Presence of a sexually transmitted infection (STI), symptomatic yeast infection, or bacterial vaginosis (BV), as diagnosed by clinical exam or laboratory testing at screening. Women with asymptomatic yeast infection or BV may be enrolled.
- Abnormal Pap smear (CIN I or higher) at screening
- Use of any spermicide or spermicidally lubricated condom within the week prior to enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
Safety: genital findings, epithelial disruption, vaginal flora changes, genital shedding, inflammation & self-reported symptoms. Assessments were made weekly at days 7, 14 & 21.
|
Acceptability: interviewer-administered questionnaires & daily diaries. Interviewer-administered questionnaires assessed at day 21 & daily diaries were assessed at days 14 and 21.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Janneke van de Wijgert, Ph.D., International Antiviral Therapy Evaluation Center
- Hauptermittler: Gita Ramjee, Ph.D, Medical Research Council
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- HIV-Seropositivität
Andere Studien-ID-Nummern
- Population Council #297
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Port Said UniversityRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Ägypten
-
Boston Children's HospitalSterileCare Inc.Anmeldung auf EinladungZentrale Linienkomplikation | Central Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
Klinische Studien zur Karaguard (PC-515)
-
Population CouncilCenters for Disease Control and Prevention; Ministry of Health, Thailand; National... und andere MitarbeiterAbgeschlossen
-
Population CouncilUnited States Agency for International Development (USAID); Bill and Melinda...AbgeschlossenHIV-Infektionen | Sexuell übertragbare Krankheiten | AIDS | HIV-SerokonversionSüdafrika
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand und andere MitarbeiterAbgeschlossenHIV-Infektionen | Herpes simplex | Syphilis | Trichomonas-Vaginitis | Chlamydia Trachomatis | Neisseria gonorrhoeaeThailand
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand und andere MitarbeiterAbgeschlossenHIV-Infektionen | Syphilis | Trichomonas-Vaginitis | Chlamydia Trachomatis | Nesseria GonorrhoeThailand
-
Population CouncilNational Institute of Allergy and Infectious Diseases (NIAID); United States... und andere MitarbeiterAbgeschlossenHIV-Infektionen | Syphilis | Trichomonas-Vaginitis | Chlamydia Trachomatis | Neisseria gonorrhoeaeSüdafrika
-
TretheraRekrutierungOnkologie | Solider Tumor, ErwachsenerVereinigte Staaten
-
University Hospital, Basel, SwitzerlandAbgeschlossenHerzfehler; Mit DekompensationSchweiz
-
KU LeuvenAmsterdam UMC, location VUmc; Agentschap voor Innovatie door Wetenschap en Technologie und andere MitarbeiterUnbekanntBewohner von Pflegeheimen mit PalliativpflegebedarfBelgien
-
Massachusetts General HospitalNational Cancer Institute (NCI)Abgeschlossen
-
Hadassah Medical OrganizationAbgeschlossen